Pharma Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation By Angus Liu Jun 13, 2025 10:50am Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

Nonetheless, though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then. Merck is also working on different strategies to drive Keytruda's long-term ...

Key Takeaways Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 ...

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce ...

VIENNA, Va., June 18, 2025--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.

Pharma FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer By Angus Liu Jun 9, 2025 10:50am Merck & Co. Keytruda Bristol Myers Squibb Opdivo ...

RAHWAY, N.J., June 13, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® ...

Merck has obtained the Food and Drug Administration’s permission for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced ...

Keytruda plus Trodelvy cuts triple-negative breast cancer (TNBC) progression risk by 35%: In the ASCENT-04/KEYNOTE-D19 trial, the combination of Keytruda plus Trodelvy significantly outperformed ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) to treat a new ...

India Business News: Dr. Reddy's Laboratories and Alvotech have partnered to co-develop, manufacture, and commercialize a biosimilar of Keytruda (pembrolizumab), a signifi ...